2026-04-14T07:14:17Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/552992026-04-11T00:24:46Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Rodríguez-Sevilla, Juan José author Fernández Rodríguez, M. Concepción author Bento, Leyre author Díez-Feijóo, Ramón author Felipe Pinzon, Sergio author Gibert Fernandez, Joan, 1988- author Fernández-Ibarrondo, Lierni author Lafuente, Marta author Ferrer Del Alamo, Ana author Sánchez González, Blanca author Gimeno Vázquez, Eva author Sainz, Juan author Ramos-Asensio, Rafael author García, Juan Fernando author Colomo Saperas, Luis Alberto author Bellosillo Paricio, Beatriz author Gutiérrez, Antonio author Salar, Antonio author 2023-01-17T08:02:44Z 2023-01-17T08:02:44Z 2022 [AHEAD] Data de publicació electrónica: 19-10-2022 Several clinical risk models have been proposed to predict outcome in follicular lymphoma (FL). The development of Next Generation Sequencing (NGS) technologies has allowed the integration of somatic gene mutations in clinical scores to build genotyped-based risk models, such as m7-FLIPI. We explored four clinical or clinicogenetic risk models in patients with symptomatic FL who received frontline immunochemotherapy. Out of 191 patients with FL grade 1-3a, 109 were successfully genotyped. Treatment consisted on rituximab (R) plus CVP/CHOP (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high-risk in FLIPI, FLIPI-2, PRIMA-PI or m7-FLIPI were 39.3%, 14%, 30.3%, 22%, respectively. No case with low-intermediate FLIPI was upgraded in m7-FLIPI, but 18 out of 42 higher-risk patients in FLIPI were downgraded to low-risk m7-FLIPI. Sensitivity and specificity for the prediction of POD24 was highest for FLIPI. The discrimination for progression free survival (PFS) and overall survival (OS) was best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only R-B patients, m7-FLIPI had higher discrimination for PFS and OS. Thus, FLIPI remains as the clinical risk score with higher discrimination in advanced FL patients treated with immunochemotherapy, but the performance of m7-FLIPI should be further investigated in patients treated with R-B. Limfomes -- Tractament Immunoteràpia Genètica Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy